ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Massachusetts » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Massachusetts

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ALAN WEINSHEL M.D.

Cardiovascular Disease

13,677

$674K

562
470 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$49
Average prescription price

Avg: $56

WILLIAM CAPLAN M.D.

Cardiovascular Disease

12,500

$521K

740
665 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 25%

$42
Average prescription price

Avg: $56

JOHN TEMTE M.D.

Cardiovascular Disease

11,863

$610K

391
335 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 25%

$51
Average prescription price

Avg: $56

ERIC JOHNSON MD

Cardiovascular Disease

10,498

$547K

648
573 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$52
Average prescription price

Avg: $56

BASSEM NASSER M.D.

Cardiovascular Disease

10,311

$528K

615
516 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

2%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$51
Average prescription price

Avg: $56

GEORGE CHILAZI M.D.

Cardiovascular Disease

10,135

$391K

801
676 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 25%

$39
Average prescription price

Avg: $56

MARK DESNOYERS MD

Cardiovascular Disease

9,838

$480K

563
465 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$49
Average prescription price

Avg: $56

LAWRENCE MOSCHITTO M.D.

Cardiovascular Disease

9,754

$543K

504
461 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $56

ROBERT SUMNER MD

Cardiovascular Disease

9,467

$557K

355
303 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 25%

$59
Average prescription price

Avg: $56

ADAM CEREL MD

Cardiovascular Disease

8,734

$506K

673
537 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$58
Average prescription price

Avg: $56

FRANK STRACCIA DO

Cardiovascular Disease

8,673

$487K

369
275 are 65+

15%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $56

FRANCISCO GIL MD

Cardiovascular Disease

8,540

$448K

274
190 are 65+

10%
patients receiving schedule two controlled substances

Avg: 1%

9%
patients receiving schedule three controlled substances

Avg: 0%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 25%

$52
Average prescription price

Avg: $56

DAVID CRISS MD

Cardiovascular Disease

8,344

$401K

682
613 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 25%

$48
Average prescription price

Avg: $56

ANN GRADY M.D.

Cardiovascular Disease

8,262

$397K

332
271 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$48
Average prescription price

Avg: $56

THOMAS MCNULTY M.D.

Cardiovascular Disease

8,135

$424K

293
239 are 65+

15%
patients receiving schedule two controlled substances

Avg: 1%

8%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 25%

$52
Average prescription price

Avg: $56

ALEXANDER ALTSCHULLER MD

Cardiovascular Disease

8,074

$424K

408
385 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$53
Average prescription price

Avg: $56

MARK WOLFE M.D.

Cardiovascular Disease

8,046

$726K

839
777 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 25%

$90
Average prescription price

Avg: $56

GREGORY RUSSELL MD

Cardiovascular Disease

7,883

$330K

469
361 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 25%

$42
Average prescription price

Avg: $56

LESTER SHOAP MD

Cardiovascular Disease

7,880

$606K

515
461 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$77
Average prescription price

Avg: $56

RANDALL KAUFMAN MD

Cardiovascular Disease

7,847

$395K

264
221 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

11%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$50
Average prescription price

Avg: $56

MARK HODGMAN M.D.

Cardiovascular Disease

7,353

$400K

386
342 are 65+

9%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 25%

$54
Average prescription price

Avg: $56

ISHWARA SHARMA M.D.

Cardiovascular Disease

7,286

$326K

448
356 are 65+

12%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 25%

$45
Average prescription price

Avg: $56

SALIL MIDHA MD

Cardiovascular Disease

7,225

$392K

447
432 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 25%

$54
Average prescription price

Avg: $56

SCOTT LUTCH M.D.

Cardiovascular Disease

6,658

$374K

413
384 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 25%

$56
Average prescription price

Avg: $56

JOHN TERZIAN MD

Cardiovascular Disease

6,507

$458K

236
187 are 65+

10%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 25%

$70
Average prescription price

Avg: $56

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank